title: Statin discontinuation in nursing home residents with advanced dementia.
abstract: OBJECTIVE
  To describe patterns of, and factors associated with, statin use and discontinuation in nursing home (NH) residents progressing to advanced dementia and followed for at least 90 days.
  
  
  METHODS
  Retrospective inception cohort using a dataset linking 2007 to 2008 Minimum Data Set (MDS) to Medicare denominator and Part D files.
  
  
  METHODS
  All NHs in five states (Minnesota, Massachusetts, Pennsylvania, California, Florida).
  
  
  METHODS
  NH residents with dementia.
  
  
  METHODS
  Residents who developed advanced dementia were observed from baseline (date of progression to very severe cognitive impairment with eating problems) and followed for at least 90 days to statin discontinuation or death. Logistic regression was used to identify baseline factors associated with statin use. Cox proportional hazard regression was used to identify factors associated with time to statin discontinuation.
  
  
  RESULTS
  Of 10,212 residents, 16.6% (n = 1,699) used statins. Greater odds of statin use were associated with having diabetes mellitus (adjusted odds ratio (AOR) = 1.24, 95% confidence interval (CI) = 1.09-1.40), stroke (AOR = 1.31, 95% CI = 1.16-1.48), and hypertension (AOR = 1.35, 95% CI = 1.18-1.54); hospice enrollment was associated with lower odds (AOR = 0.75, 95% CI = 0.64-0.89). In follow-up, 37.2% (n = 632) discontinued statins. Median time to discontinuation was 36 days (interquartile range 12-110 days). Shorter time to discontinuation was associated with hospitalization in past 30 days (adjusted hazard ratio (AHR) = 1.67, 95% CI = 1.40-1.99) and more daily medications (AHR = 1.02, 95% CI = 1.01-1.04). When statins were discontinued, 15.0% (n = 95) of residents stopped only statins, and 47.5% (n = 300) stopped at least one other medication.
  
  
  CONCLUSIONS
  Most NH residents who use statins at the time of progression to advanced dementia continue use in follow-up.
authors.affiliation: University of Massachusetts Medical School, Worcester, Massachusetts, Massachusetts.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Tjia
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Cutrona
authors.forename: Daniel
authors.initials: D
authors.lastname: Peterson
authors.forename: George
authors.initials: G
authors.lastname: Reed
authors.forename: Susan E
authors.initials: SE
authors.lastname: Andrade
authors.forename: Susan L
authors.initials: SL
authors.lastname: Mitchell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D015331:Cohort Studies; D015897:Comorbidity; D003704:Dementia / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D018450:Disease Progression; D057915:Drug Substitution / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006707:Homes for the Aged; D017051:Hospice Care / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D018447:Medical Futility; D008609:Mental Status Schedule; D009735:Nursing Homes; D016017:Odds Ratio; D012189:Retrospective Studies; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: dementia; pharmaceuticals; statins